"All of these sort of regular things that biotech companies do, like snapping up patents so that they can get investor dollars moving forward, they’re intersecting with this culture in the psychedelics world, which is sort of anti-ownership. These forces will clash. They oppose with one another.” –Shayla Love, Vice Media

Shayla Love is a senior staff writer at Vice Media whose writing has appeared in The Washington Post, The Atlantic, Harper’s Magazine, The Guardian, and more. Her recent focus has been the field of psychedelics and how they exist and interact with the forces of what some refer to as late-stage capitalism. Shayla discussed whether there is a way to corporatize psychedelics responsibly, who has the most to gain in the new landscape of psychedelic capitalism, why the for-profit entity known as Compass Pathways attempted to patent a form of synthetic psilocybin, how and why the accompanying challenge to this patent from a group called FTO, or Freedom to Operate, originated, whether state decriminalization of psychedelics is at odds with federal medicalization, and more.